Pharmaceuticals, Biotechnology and Life Sciences
On January 4, 2017, TiGenix received a transparency notification from related companies Takeda Pharmaceutical Company Limited/Takeda Pharmaceuticals International AG, following…
Argenx, a European biopharmaceutical company focused on drugs for the treatment of cancer and autoimmune diseases, has initiated a Phase…
U.S. Patent and Trade Office (USPTO) has decided to uphold Celyad’s U.S. Patent No. 9,181,527, relating to allogeneic human primary…
Author: Anna Michael, The Study Abroad Portal The Study Abroad Portal helps students worldwide to make the right decision with…
Ipsen has acquired global oncology assets from Merrimack Pharmaceuticals. This acquisition includes Merrimack’s key marketed product Onivyde (irinotecan liposome injection)…
e-Therapeutics plc, the drug discovery company, has made further steps in transitioning its business as it picked Amgen Inc.’s Corporate Development Executive Director, Dr. Raymond Barlow as its new Chief Executive Officer (CEO) who assume his position before May 1, 2017.
AB Sciences has more reasons to believe that its protein kinase inhibitor (PKI) masitinib could have FDA’s further clearence, as the results from the pivotal phase 3 study have been published in highly regarded independent general medical journal, The Lancet.
Bristol-Myers Squibb (BMS) and GeneCentric Diagnostics have teamed up to explore the possibility of GeneCentric’s Cancer Subtype Platform (CSP) could identify translational biomakers for Opdivo, that could help for future clinical trials.
Novartis and Ionis Pharmaceuticals with its affiliate Akcea Therapeutics have signed an agreement for licensing two novel treatments for reducing cardiovascular risk in patients with high levels of lipoproteins known as Lp(a) and ApoCIII.
Sanofi and Regeneron Pharmaceuticals are going to will appeal the injunction granted on Friday by the U.S. District Court for the District of Delaware preventing the marketing, selling or manufacturing of Praluent in the U.S. during the term of two Amgen patents.